OTV

OTV does not publicly name its general partners or investment committee members on its website or LinkedIn. The site references 'our partners' and their collective exit track record, but individual names, backgrounds, and decision-making authority are not disclosed. An allocator would need a direct meeting to map the investment team.

The firm has not published a formal co-investment policy. Its descriptions of reviewing decks and inviting founders for meetings suggest it evaluates opportunities directly as a lead or syndicate participant. Whether it offers side-car co-investment slots to its LPs or joins rounds led by other venture firms is not detailed in public materials.

OTV's dual-office structure in Tel Aviv and New York anchors its sourcing strategy. Israel produces a disproportionate share of digital health patents and clinical AI startups, while the US is the primary commercial market for scaling them. The firm's website does not describe academic partnerships, incubator relationships, or scout networks, but its geography suggests tight links to Israel's health-tech ecosystem and US-based healthcare systems.

OTV presents itself as a venture firm that invests directly in startups rather than as a fund-of-funds. No public reference indicates it makes commitments to other venture capital funds. The firm's investor-relations language — quarterly reports, annual summits — is consistent with a direct-investment vehicle where LPs want visibility into specific portfolio companies.

OTV's website states it focuses exclusively on digital health ventures that can make a 'significant impact on people's lives.' The firm does not mention therapeutics, medical devices, biotech, diagnostics, or health IT beyond digital. Absent any portfolio company disclosure, the avoidance of non-digital health verticals must be inferred from this narrow mandate.